{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T16:26:40Z","timestamp":1778862400758,"version":"3.51.4"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T00:00:00Z","timestamp":1655942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Objective:<\/jats:bold> Continuous lenalidomide (LEN) therapy is important to achieve a therapeutic effect in patients with multiple myeloma (MM) and non-Hodgkin lymphoma (NHL). However, despite dose adjustment according to kidney function, many patients discontinue LEN therapy because of hematological toxicity. To date, therapeutic drug monitoring (TDM) of LEN has not been performed in oncology, and no target concentration level has been yet defined. The aim of this study was to evaluate the exposure-safety relationship of LEN and determine the target concentration for toxicity.<\/jats:p><jats:p><jats:bold>Materials and Methods:<\/jats:bold> A prospective observational study was designed and implemented. Blood samples were collected at 0.5\u00a0h (trough concentration, C<jats:sub>min<\/jats:sub>) before oral administration and 1\u00a0h (C<jats:sub>1h<\/jats:sub>) thereafter on the day. Clinical data were gathered from patients\u2019 medical records and laboratory reports. Outcome measures of hematological toxicity were defined by the Common Terminology Criteria for Adverse Events. The concentration values were dichotomized by receiver operating characteristic (ROC) curve analysis, and the association between exposure and outcome was determined using the logistic regression model.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Out of the 61 patients enrolled in this study, 40 (65.57%) had MM, and 21 (34.43%) had NHL. Hematological toxicity was reported in 15 (24.59%) patients. The LEN C<jats:sub>min<\/jats:sub> showed remarkable differences (<jats:italic>p =<\/jats:italic> 0.031) among patients with or without hematological toxicity, while no association between C<jats:sub>1h<\/jats:sub> values and toxicity was noted (<jats:italic>p<\/jats:italic>&amp;gt;0.05). By ROC analysis, a C<jats:sub>min<\/jats:sub> threshold of 10.95\u00a0ng\/mL was associated with the best sensitivity\/specificity for toxicity events (AUC = 0.687; sensitivity = 0.40; specificity = 0.935). By multivariate logistic regression, an LEN C<jats:sub>min<\/jats:sub> below 10.95\u00a0ng\/mL was associated with a markedly decreased risk of hematological toxicity (&amp;lt;10.95\u00a0ng\/mL vs. &amp;gt;10.95\u00a0ng\/mL: OR = 0.023, 95% CI = 0.002\u20130.269; <jats:italic>p<\/jats:italic> = 0.003).<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> We demonstrate that the LEN trough concentration correlates with hematological toxicity, and the C<jats:sub>min<\/jats:sub> threshold for hematological toxicity (10.95\u00a0ng\/mL) is proposed. Altogether, LEN TDM appears to be a new approach to improve medication safety and achieve continuous treatment for patients with NHL or MM in routine clinical care.<\/jats:p>","DOI":"10.3389\/fphar.2022.931495","type":"journal-article","created":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T04:32:07Z","timestamp":1655958727000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Toward Therapeutic Drug Monitoring of Lenalidomide in Hematological Malignancy? Results of an Observational Study of the Exposure-Safety Relationship"],"prefix":"10.3389","volume":"13","author":[{"given":"Zaiwei","family":"Song","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aijun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinchu","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongsheng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongmei","family":"Jing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s00280-016-3068-9","article-title":"Pharmacokinetics, Safety, and Efficacy of Lenalidomide Plus Dexamethasone in Patients with Multiple Myeloma and Renal Impairment","volume":"78","author":"Bridoux","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"738693","DOI":"10.3389\/fmed.2021.738693","article-title":"Trends Analysis of Non-hodgkin Lymphoma at the National, Regional, and Global Level, 1990-2019: Results from the Global Burden of Disease Study 2019","volume":"8","author":"Cai","year":"2021","journal-title":"Front. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s40262-016-0432-1","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide","volume":"56","author":"Chen","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1182\/blood.v122.21.3234.3234","article-title":"Population Pharmacokinetics and Exposure-Safety of Lenalidomide in Patients with Multiple Myeloma, Myelodysplastic Syndromes and Mantle Cell Lymphoma","volume":"122","author":"Chen","year":"2013","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.clml.2020.03.009","article-title":"Management of Adverse Events from the Combination of Rituximab and Lenalidomide in the Treatment of Patients with Follicular and Low-Grade Non-hodgkin Lymphoma","volume":"20","author":"Cheson","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1200\/JCO.2014.59.5363","article-title":"Mechanisms of Action of Lenalidomide in B-Cell Non-hodgkin Lymphoma","volume":"33","author":"Gribben","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1248\/bpb.b20-00337","article-title":"Factors Associated with Dose Modification of Lenalidomide Plus Dexamethasone Therapy in Multiple Myeloma","volume":"43","author":"Kado","year":"2020","journal-title":"Biol. Pharm. Bull."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3904\/kjim.2009.24.1.1","article-title":"Overview of Therapeutic Drug Monitoring","volume":"24","author":"Kang","year":"2009","journal-title":"Korean J. Intern Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1097\/FTD.0000000000000499","article-title":"Phase II Clinical Trial of Lenalidomide and Dexamethasone Therapy in Japanese Elderly Patients with Newly Diagnosed Multiple Myeloma to Determine Optimal Plasma Concentration of Lenalidomide","volume":"40","author":"Kobayashi","year":"2018","journal-title":"Ther. Drug Monit."},{"key":"B10","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1182\/blood-2012-03-415661","article-title":"Combined Treatment with Lenalidomide and Epoetin Alfa in Lower-Risk Patients with Myelodysplastic Syndrome","volume":"120","author":"Komrokji","year":"2012","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1056\/NEJMoa041668","article-title":"Efficacy of Lenalidomide in Myelodysplastic Syndromes","volume":"352","author":"List","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1038\/s41375-018-0040-1","article-title":"Prevention and Management of Adverse Events of Novel Agents in Multiple Myeloma: a Consensus of the European Myeloma Network","volume":"32","author":"Ludwig","year":"2018","journal-title":"Leukemia"},{"key":"B14","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1056\/NEJMoa1300439","article-title":"Lenalidomide Plus Dexamethasone for High-Risk Smoldering Multiple Myeloma","volume":"369","author":"Mateos","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.ccr.2004.10.020","article-title":"Focus on Multiple Myeloma","volume":"6","author":"Mitsiades","year":"2004","journal-title":"Cancer Cell"},{"key":"B16","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00228-020-03014-8","article-title":"Therapeutic Drug Monitoring of Oral Targeted Antineoplastic Drugs","volume":"77","author":"Mueller-Schoell","year":"2021","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1007\/s00216-018-0866-4","article-title":"Volumetric Absorptive Microsampling as an Alternative Tool for Therapeutic Drug Monitoring of First-Generation Anti-epileptic Drugs","volume":"410","author":"Velghe","year":"2018","journal-title":"Anal. Bioanal. Chem."},{"key":"B19","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.ijantimicag.2014.12.010","article-title":"TDMx: a Novel Web-Based Open-Access Support Tool for Optimising Antimicrobial Dosing Regimens in Clinical Routine","volume":"45","author":"Wicha","year":"2015","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B20","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1186\/s12885-021-08280-y","article-title":"Measuring the Global, Regional, and National Burden of Multiple Myeloma from 1990 to 2019","volume":"21","author":"Zhou","year":"2021","journal-title":"BMC Cancer"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.931495\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T04:32:09Z","timestamp":1655958729000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.931495\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,23]]},"references-count":20,"alternative-id":["10.3389\/fphar.2022.931495"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.931495","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,23]]},"article-number":"931495"}}